References
Griffin JH, Zlokovic BV, Mosnier LO (2015) Activated protein C: biased for translation. Blood 125:2898–2907
Weiler H (2014) Inflammation-associated activation of coagulation and immune regulation by the protein C pathway. Thromb. Res. 133(Suppl):S32–S34
van Mens TE, Levi M, Middeldorp S. (2013) Evolution of factor V leiden. Thromb Haemost 110:23–30
Petäjä J, Hakala L, Rasi V, Griffin JH (1998) Circulating activated protein C in subjects with heterozygous Gln506-factor V. Haemostasis 28:31–36
Faioni E, Franchi F (1998) Activation of the protein C pathway in hereditary thrombophilia. Thromb Haemost 80:557–560
Strandberg K, Svensson PJ, Ohlin A-K (2007) Venous thromboembolism in carriers of the factor V leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity. Thromb Res 121:145–151
Meijers JCM, Herwald H (2011) Protein C inhibitor. Semin Thromb Hemost 37:349–354
Müller J et al (2012) Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay. J Thromb Haemost 10:390–398
Liaw, P. C. Y., Ferrell G, Esmon CT (2003) A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost 1:662–670
Gruber A, Griffin JH (1992) Direct detection of activated protein C in blood from human subjects. Blood 79:2340–2348
Acknowledgements
We thank J.A. Marquart and W. Kopatz for laboratory assistance.
Funding
This study was funded by the Netherlands Organisation for Scientific Research (NWO, VIDI innovative research Grant 016.126.364 awarded to S. Middeldorp).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
van Mens, T.E., Meijers, J.C.M. & Middeldorp, S. Circulating activated protein C in thrombophilia carriers. J Thromb Thrombolysis 43, 361–364 (2017). https://doi.org/10.1007/s11239-016-1472-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-016-1472-y